Clinical Trial News and Research

RSS

Resverlogix, Emerald Logic complete collaborative research program

Resverlogix Corp. today announced that it has completed a collaborative research program with Emerald Logic, a leader in quantitative analytics. Using Fast Collective Evolution Technology (FACET), Emerald Logic analyzed Resverlogix's complete clinical dataset including all measurements obtained from each of 798 patients who participated in the Company's Phase 2 clinical trials ASSERT, SUSTAIN and ASSURE.

4 Mar 2015

Lexicon updates drug development progress, reports 2014 financial results

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2014.

4 Mar 2015

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Pharma Two B announced today that enrollment has been completed in the company's Phase IIb study of P2B001 for the treatment of early stage Parkinson's disease. One hundred and forty-nine patients enrolled in the study conducted at 29 clinical sites throughout the US and Israel.

4 Mar 2015

Non-drug approaches work better in people with Alzheimer's disease, dementia

Doctors write millions of prescriptions a year for drugs to calm the behavior of people with Alzheimer's disease and other types of dementia. But non-drug approaches actually work better, and carry far fewer risks, experts conclude in a new report.

4 Mar 2015

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, Rigel reported a net loss of $22.3 million, or $0.25 per share, compared to a net loss of $16.9 million, or $0.19 per share, in the fourth quarter of 2013.

3 Mar 2015

FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of primary peritoneal cancers.

3 Mar 2015

Autism Speaks' affiliate DELSIA announces new funding for clinical trial of cognitive video game

Autism Speaks' not-for-profit affiliate Delivering Scientific Innovation for Autism has announced new funding for clinical testing of a cognitive video game designed to improve executive function skills in children and adolescents with autism.

3 Mar 2015

Alizé Pharma announces launch of AZP-531 Phase II trial in patients with Prader-Willi syndrome

Alizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, today announces the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome.

3 Mar 2015

Kyprolis demonstrates superiority over velcade in patients with relapsed multiple myeloma in head-to-head endeavor trial

Patients Receiving Kyprolis Lived Twice as Long without Disease Progression

2 Mar 2015

Study shows importance of disclosing physician conflicts of interest in MS ISCTs to potential participants

If you're one of the nearly half a million Americans living with multiple sclerosis (MS) - a slowly disabling disease of the central nervous system - you are likely dependent on disease-modifying drugs to prevent symptoms such as vision problems, balance issues and weakness. Often, these treatments have been developed through pharmaceutical industry-sponsored clinical trials (ISCT) in collaboration with academic or private practice physicians who care for MS patients.

2 Mar 2015

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

2 Mar 2015

WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, congratulates our partner TaiMed Biologics for receiving breakthrough therapy designation from the U.S. FDA for ibalizumab (TMB355).

28 Feb 2015

Researchers investigate efficiency of drug research and development

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could be responsible.

28 Feb 2015

Researchers outline personalized surgical approach to ovarian cancer

A surgical algorithm developed and implemented by ovarian cancer specialists at The University of Texas MD Anderson Cancer Center dramatically increases the frequency of complete removal of all visible tumor - a milestone strongly tied to improved survival.

28 Feb 2015

TxCell invited to speak at largest US meeting for investors in emerging growth companies

In the presentation, Damian Marron will provide an overview of TxCell and its personalized T cell immunotherapy platform ASTrIA. Additional details will also be provided to institutional investors in one on one meetings at the conference.

27 Feb 2015

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years.

27 Feb 2015

Feast-or-famine diet may extend lifespan, improve age-related diseases

University of Florida Health researchers have found that putting people on a feast-or-famine diet may mimic some of the benefits of fasting, and that adding antioxidant supplements may counteract those benefits.

27 Feb 2015

NIAID partners with Liberian government to test ZMapp drug for Ebola virus disease

In partnership with the Liberian government, the National Institute of Allergy and Infectious Diseases today launched a clinical trial to obtain safety and efficacy data on the investigational drug ZMapp as a treatment for Ebola virus disease. The study, which will be conducted in Liberia and the United States, is a randomized controlled trial enrolling adults and children with known Ebola virus infection.

27 Feb 2015

ERT signs definitive agreement to acquire PHT

ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, and PHT Corporation, the eClinical innovator leading the adoption of patient-driven mobile apps for improved clinical research, announced today that they have signed a definitive agreement under which ERT will acquire PHT.

27 Feb 2015

New cancer drug enters phase I clinical trials in humans

A new drug that prompts cancer cells to self-destruct while sparing healthy cells is now entering phase I clinical trials in humans. The drug, called PAC-1, first showed promise in the treatment of pet dogs with spontaneously occurring cancers, and is still in clinical trials in dogs with osteosarcoma.

27 Feb 2015

Clinical Trial News and Research

Resverlogix, Emerald Logic complete collaborative research program

Lexicon updates drug development progress, reports 2014 financial results

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Non-drug approaches work better in people with Alzheimer's disease, dementia

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

Autism Speaks' affiliate DELSIA announces new funding for clinical trial of cognitive video game

Alizé Pharma announces launch of AZP-531 Phase II trial in patients with Prader-Willi syndrome

Kyprolis demonstrates superiority over velcade in patients with relapsed multiple myeloma in head-to-head endeavor trial

Study shows importance of disclosing physician conflicts of interest in MS ISCTs to potential participants

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

Researchers investigate efficiency of drug research and development

Researchers outline personalized surgical approach to ovarian cancer

TxCell invited to speak at largest US meeting for investors in emerging growth companies

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Feast-or-famine diet may extend lifespan, improve age-related diseases

NIAID partners with Liberian government to test ZMapp drug for Ebola virus disease

ERT signs definitive agreement to acquire PHT

New cancer drug enters phase I clinical trials in humans

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer